Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.

Related Clinical Trial
Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) A Study Of Inotuzumab Ozogamicin Versus Investigator’s Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia Effect of Vitamin D Diffiency on Oral Mucosa in Patients Recieving Methotrexate Chemotherapy Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia: A Study of Children With Refractory or Relapsed ALL Therapy Protocol Acute Lymphoblastic Leukemia Stem Cell Transplantation International Pharmacogenetically Based Dosing of Thiopurines in Childhood Acute Lymphoblastic Leukemia ItaliaN Observational Study of Patients With Acute Lymphoblastic Leukemia Treated With Anti-CD22 Immunoconjugate Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL) Physical Activity to Modify Sequelae and Quality of Life in Childhood Acute Lymphoblastic Leukemia Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia. Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL) Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) Feasibility of Risk-Adapted Therapy in Young Adult Acute Lymphoblastic Leukemia: a Multicenter Trial Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients Rapamycin in Relapsed Acute Lymphoblastic Leukemia Treatment of Childhood Acute Lymphoblastic Leukemia Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia The Influence of Thiopurine Methyltransferase Activity on Toxicity After High-dose Methotrexate in Childhood Acute Lymphoblastic Leukemia CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL) Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) Neurostimulation In Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL) Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC) Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia Pharmacokinetic Profile of Vincristine Administered With Imatinib for Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) Compared to That Without Imatinib for Bcr-Abl Negative ALL Phase III B in Acute Lymphoblastic Leukemia The Effects of Honey on Febrile Neutropenia in Children With Acute Lymphoblastic Leukemia Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia Treatment of Acute Lymphoblastic Leukemia in Children PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Treatment of High Risk Adult Acute Lymphoblastic Leukemia Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 A Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL) The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL) Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph ‘Negative in Elderly Patients (> 55 Years) Home-exercise Program for Children and Adolescent Survivors of Acute Lymphoblastic Leukemia The Association Between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in NOPHOALL 2008 A Study Evaluating KTE-X19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Treatment of Older Adults With Acute Lymphoblastic Leukemia Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+ CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia Pharmacogenetic Analysis of Korean Pediatric Patients With Acute Lymphoblastic Leukemia PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic Leukaemia Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) Osteonecrosis in Children With Acute Lymphoblastic Leukemia Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia Effect of Omega-3 Fatty Acids on Methotrexate Induced Hepatotoxicity in Children With Acute Lymphoblastic Leukemia Treatment for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia A Study in Adults With Untreated Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia Relapse in Sweden 2003-2007 The Effects of Ankle Foot Orthoses on Gait Efficiency in Children With Acute Lymphoblastic Leukemia and Foot Drop Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia Postural Control Under Different Cognitive Loads in Adult Survivors of Acute Lymphoblastic Leukemia and Age-Matched Healthy Individuals Genomic Changes in Childhood Acute Lymphoblastic Leukemia Role of the Microparticles and of Tissue Factor in the Pro-thrombotic Phenotype and the Thromboembolic Complications During the Acute Lymphoblastic Leukemia in Children. Allogeneic Stem Cell Transplantation (SCT) With Treosulfan, VP-16 and Cyclophosphamid for Patients With Acute Lymphoblastic Leukemia (ALL) Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia A Clinical Study of SHP674 in Patients With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Neurologic Morbidity and Disability in Acute Lymphoblastic Leukemia Survivors Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia Quality of Life Study for Adult Patients With Acute Lymphoblastic Leukemia Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia FoxO3a and PU.1 in Acute Lymphoblastic Leukemia Clinical Significance of Occult Central Nervous System Disease In Adult Acute Lymphoblastic Leukemia Genome-wide Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Lymphoblastic Leukemia Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Brief Title

Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.

Official Title

Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor.

Brief Summary

      Drug resistance resulting from emergence of Imatinib-resistant BCR-ABL clones is a
      significant problem in Ph positive ALL patients because after a very good initial response to
      one TKI inhibitor, many patients relapse within one year, relapse being almost always
      associated with a BCR-ABL kinase domain point mutation. The patients who relapse after
      treatment with one TKI can be rescued to remission with another TKI, but the second remission
      is usually shorter than the previous one. A more potent TKI inhibitor, and pan-active not
      only on all the BCR-ABL variants (including the second generation TKI resistant T315I
      mutant), but also on others molecular targets can do better. In this context, Ponatinib is a
      novel synthetic orally active tyrosine kinase inhibitor (TKI), specifically developed to
      inhibit BCR-ABL, the fusion protein that is the product of the Philadelphia chromosome (Ph)
      in chronic myeloid leukemia (CML) and in a subset of acute lymphoblastic leukemia (Ph+ ALL).
      It potently inhibits the BCR-ABL protein as well as mutated forms of the protein that arise
      in patients resistant to prior therapies with TKIs. Ponatinib has been demonstrated to
      inhibit all the mutations that have been detected so far, in vitro and in vivo and to
      uniformly suppress the emerge of single-mutant clones in a mutagenesis assay. In the Phase II
      study, 41% of Philadelphia chromosome positive acute lymphoblastic leukemia patients treated
      with Ponatinib achieved major hematologic response, 47% had a major cytogenetic response, 38%
      obtained a complete cytogenetic response, showing that Ponatinib provides significant benefit
      despite previous intolerance or refractoriness to other TKIs. The Phase I trial showed that
      patients with a more recent diagnosis had increased rates of major molecular response: 79%
      for 14 patients with 0 to 5 years since diagnosis vs. 29% for 14 patients with more than 5 to
      9 years since diagnosis (P=0.02) and 27% for 15 patients with more than 9 to 24 years since
      diagnosis (P=0.009). These characteristics support the hypothesis for a role of Ponatinib not
      only in patients resistant to prior TKI therapy but also in untreated ALL Ph+ patients, in
      order to prevent the emergence of resistant caused by the selection of mutated Ph+ clones and
      in order to avoid rapid progression of the disease.
    

Detailed Description

      This is a multi-center, phase 2, single arm unblinded trial of oral Ponatinib in patients
      with Ph+ Acute Lymphoblastic Leukemia. Patients will receive daily oral administration of
      Ponatinib at a dose of 45 mg/day for 6 weeks (defined as one course) for 8 courses, same dose
      and schedule, for a total of 48 weeks. Each patient will be followed for the subsequent 24
      months, every 3 month, providing survival information and monitoring serious adverse event.

      Each patient should be treated for a minimum of 6 weeks. Then a patient can be discontinued
      in the following situation:

        -  at the end of first course (6 weeks), in case of lack of CHR;

        -  at the end of third course (18 weeks), in case of lack of CCgR;

        -  any time in case of loss of CHR or CCgR.

      If they remain on therapy after 48 weeks, they will be able to continue treatment during the
      extension phase of the study, if it is of interest of the patient, or they will be allowed to
      receive any treatment that is in their interest. For all the patients remaining on trial,
      response, outcome and toxicity will be followed for the subsequent 24 months.The 6-weeks
      periodicity must be rigidly respected, irrespective of the temporary discontinuation of study
      drug (eg, if a patient will take Ponatinib only for 4 weeks and will remain off-treatment for
      the subsequent two weeks because of AE, when the 7th week begins this patient will restart
      Ponatinib as a second course, as per protocol). Prednisone (P) will be administered to all
      patients for 7-14 days, before Ponatinib, so as to make it possible to wait for the results
      of cytogenetic and molecular tests, and to evaluate the response to P alone, hence for
      another 21 days. Intrathecal therapy (IT) with MTX/AraC/DEX is mandatory, every 28 days, in
      patients without clinical-cytologic evidence of meningeal involvement. In patients with CNS
      disease, IT is performed twice weekly until a complete clearance of cerebrospinal fluid blast
      cells is achieved, hence once weekly for 4 weeks, hence once monthly.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Proportion of patients who are in Complete Hematological Response (CHR).

Secondary Outcome

 The rate of Complete Hematological Response (CHR).

Condition

Philadelphia Positive

Intervention

Ponatinib

Study Arms / Comparison Groups

 Ponatinib
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

44

Start Date

October 2014

Completion Date

November 2019

Primary Completion Date

November 2019

Eligibility Criteria

        Inclusion Criteria:

          1. To be classified as having Ph+ ALL, patients must have >20% blasts in bone marrow at
             the time of diagnosis and no prior history of CML.

          2. Patients with previously untreated Ph+ and/or BCR/ABL + ALL:

               -  age ≥ 60 years old or

               -  age ≥ 18 years old, but unfit for program of intensive therapy and allogeneic SCT

          3. Adequate hepatic function as defined by the following criteria:

               -  total serum bilirubin ≤1.5 x upper limit of normal (ULN), unless due to Gilbert's
                  syndrome

               -  alanine aminotransferase (ALT) ≤2.5 × ULN

               -  aspartate aminotransferase (AST) ≤2.5 × ULN.

          4. Adequate pancreatic function as defined by the following criterion:

             - serum lipase and amylase ≤1.5 × ULN.

          5. For females of childbearing potential, a negative pregnancy test must be documented
             prior to randomization.

          6. Female and male patients who are fertile must agree to use an effective form of
             contraception with their sexual partners from randomization through 4 months after the
             end of treatment.

          7. Signed written informed consent according to ICH/EU/GCP and national local laws.

        Exclusion Criteria:

          1. WHO performance status ≤ 50% (Karnofsky) or ≥ 3 (ECOG).

          2. Active HBV or HCV hepatitis, or AST/ALT ≥ 2.5 x ULN and bilirubin ≥ 1.5 x ULN.

          3. History of acute pancreatitis within 1 year of study or history of chronic
             pancreatitis.

          4. History of alcohol abuse.

          5. Ongoing or active infections.

          6. Uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL).

          7. Clinically significant, uncontrolled, or active cardiovascular disease, specifically
             including, but not restricted to:

               -  any history of myocardial infarction, stroke, or revascularization

               -  unstable angina or transient ischemic attack within 6 months prior to enrollment

               -  congestive heart failure within 6 months prior to enrollment, or left ventricular
                  ejection fraction (LVEF) less than lower limit of normal per local institutional
                  standards within 6 months prior to enrollment

               -  history of clinically significant (as determined by the treating physician)
                  atrial arrhythmia

               -  any history of ventricular arrhythmia

               -  any history of venous thromboembolism including deep venous thrombosis or
                  pulmonary embolism .

          8. Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg).
             Patients with hypertension should be under treatment on study entry to effect blood
             pressure control.

          9. Taking medications that are known to be associated with Torsades de Pointes.

         10. Taking any medications or herbal supplements that are known to be strong inhibitors of
             CYP3A4 within at least 14 days before the first dose of ponatinib.

         11. Creatinine level > 2.5mg/dl or Glomerular Filtration Rate (GFR) < 20 ml/min or
             proteinuria > 3.5 g/day.

         12. Impairment of gastrointestinal (GI) function, or a GI disease that may significantly
             alter the absorption of study drugs (e.g. rare hereditary problems of galactose
             intolerance , the Lapp lactase deficiency or glucose-galactose malabsorption, severe
             malabsorption syndrome, or extended small bowel resection).

         13. Patients who are currently receiving treatment with any of the medications listed in
             Appendix E if the medications cannot be either discontinued or switched to a different
             medication prior to starting study drug. The medications listed in Appendix E have the
             potential to prolong QT.

         14. Patients who have received any investigational drug ≤ 4 weeks.

         15. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or
             who have not recovered from side effects of such therapy.

         16. Patients who are pregnant or breast feeding and adults of reproductive potential not
             employing an effective method of birth control (women of childbearing potential must
             have a negative serum pregnancy test within 48 hrs prior to administration of
             Ponatinib). Post menopausal women must be amenorrhoeic for at least 12 months to be
             considered of non-childbearing potential. Male and female patients must agree to
             employ an effective barrier method of birth control throughout the study and for up to
             4 months following discontinuation of study drugs.

         17. Patients with a history of another primary malignancy that is currently clinically
             significant or currently requires active intervention.

         18. Patients unwilling or unable to comply with the protocol.
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Michele Baccarani, Pr., , 

Location Countries

Italy

Location Countries

Italy

Administrative Informations


NCT ID

NCT01641107

Organization ID

LAL1811

Secondary IDs

2012-002761-35

Responsible Party

Sponsor

Study Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto


Study Sponsor

Michele Baccarani, Pr., Principal Investigator, Dpt of Hematology and Oncology "Seràgnoli", "Sant'Orsola-Malpighi" University Hospital of Bologna


Verification Date

October 2018